View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 09, 2017
Document And Entity Information
Entity Registrant Name	Imprimis Pharmaceuticals, Inc.
Entity Central Index Key	0001360214
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,065,415
Trading Symbol	IMMY
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 4,165	$ 8,853
Restricted cash and short-term investments	200	200
Accounts receivable, net	2,856	2,921
Inventories	1,832	1,841
Assets held for sale	520
Prepaid expenses and other current assets	786	938
Total current assets	10,359	14,753
Property, plant and equipment, net	6,567	7,295
Intangible assets, net	2,934	2,972
Investment in Eton Pharmaceuticals, Inc.	5,509
Goodwill	2,227	2,227
TOTAL ASSETS	27,596	27,247
Current liabilities
Accounts payable and accrued expenses	3,344	3,538
Accrued payroll and related liabilities	1,481	1,638
Deferred revenue and customer deposits	8	91
Current portion of deferred acquisition obligation and accrued interest	158	207
Current portion of note payable, net of unamortized debt discount		3,973
Current portion of capital lease obligations, net of unamortized discount	526	458
Total current liabilities	5,517	9,905
Capital lease obligations, net of current portion and unamortized discount	1,038	1,318
Deferred acquisition obligation, net of current portion		52
Accrued expenses, net of current portion	667	667
Deferred tax liability	880	936
Note payable and paid-in-kind interest, net of unamortized debt discount and current portion	11,848	7,937
TOTAL LIABILITIES	19,950	20,815
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 90,000,000 shares authorized, 20,065,415 and 18,627,915 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	20	19
Additional paid-in capital	87,999	83,264
Accumulated deficit	(80,373)	(76,851)
TOTAL STOCKHOLDERS' EQUITY	7,646	6,432
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 27,596	$ 27,247

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	20,065,415	18,627,915
Common stock, shares outstanding	20,065,415	18,627,915

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues:
Sales, net	$ 6,849	$ 4,902	$ 12,938	$ 9,283
License revenues	8	5	16	5
Total revenues	6,857	4,907	12,954	9,288
Cost of sales	(3,288)	(2,172)	(6,645)	(4,421)
Gross profit	3,569	2,735	6,309	4,867
Operating expenses:
Selling and marketing	1,999	2,270	4,439	4,170
General and administrative	4,486	4,397	8,857	8,337
Research and development	101	76	261	122
Total operating expenses	6,586	6,743	13,557	12,629
Loss from operations	(3,017)	(4,008)	(7,248)	(7,762)
Other income (expense):
Interest expense, net	(767)	(631)	(1,555)	(1,260)
Change in fair value of derivative liabilities				(113)
Equity in loss of Eton Pharmaceuticals	(216)		(216)
Gain on deconsolidation of Eton Pharmaceuticals	5,725		5,725
Loss on sale of assets	(269)		(284)
Total other income (expense), net	4,473	(631)	3,670	(1,373)
Income (loss) before income taxes	1,456	(4,639)	(3,578)	(9,135)
Income tax benefit, net	28		56
Net income (loss)	$ 1,484	$ (4,639)	$ (3,522)	$ (9,135)
Basic net income (loss) per share of common stock	$ 0.07	$ (0.35)	$ (0.18)	$ (0.77)
Diluted net income (loss) per share of common stock	$ 0.06	$ (0.35)	$ (0.18)	$ (0.77)
Weighted average number of shares of common stock outstanding, basic	20,209,821	13,332,645	19,572,051	11,870,037
Weighted average number of shares of common stock outstanding, diluted	23,177,881	13,332,645	19,572,051	11,870,037

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,522)	$ (9,135)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of furniture and equipment	659	351
Amortization of intangible assets	181	355
Non-cash gain on contingent acquisition obligation		(81)
Deferred income taxes	(56)
Amortization of debt issuance costs and discount	632	526
Paid-in-kind interest added to principal of note payable		101
Gain from the deconsolidation of Eton Pharmaceuticals, Inc.	(5,725)
Investment loss from Eton Pharmaceuticals, Inc.	216
Loss on write down of assets held for sale	111
Loss on sale of assets	173
Change in fair value of derivative liabilities		113
Stock-based compensation	1,617	2,225
Changes in assets and liabilities, net asset sales:
Accounts receivable	65	(1,082)
Inventories	(404)	(29)
Prepaid expenses and other current assets	202	297
Accounts payable and accrued expenses	(194)	1,570
Accrued payroll and related liabilities	(157)	(68)
Deferred revenue and customer deposits	(83)	(39)
NET CASH USED IN OPERATING ACTIVITIES	(6,285)	(5,068)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments on Pharmacy Creations contingent acquisition obligation		(100)
Investment in patent and trademark assets	(143)	(135)
Investment in license assets	(50)
Purchases of property, plant and equipment	(322)	(5,745)
NET CASH USED IN INVESTING ACTIVITIES	(515)	(5,980)
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations	(305)	(14)
Net proceeds from public equity offering	2,940	11,088
Payments on Park deferred acquisition obligation	(101)	(97)
Principal payments on note payable	(601)
Proceeds from convertible note payable, net of issuance costs		2,772
Net proceeds from exercise of warrants and stock options, net of taxes remitted for RSU's	179	55
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,112	13,804
NET CHANGE IN CASH AND CASH EQUIVALENTS	(4,688)	2,756
CASH AND CASH EQUIVALENTS, beginning of period	8,853	2,685
CASH AND CASH EQUIVALENTS, end of period	4,165	5,441
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes		9
Cash paid for interest	901	616
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of embedded conversion feature recorded as debt discount and derivative liability		2,322
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering		2,646
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability		675
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering		464
Issuance of common stock and to settle contingent acquisition obligation related to the purchase of PC		302
Issuance of stock options for consulting services included in accounts payable and accrued expenses		23
Purchase of property, plant and equipment included in accounts payable and accrued expenses		$ 277

Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

NOTE 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Company and Background

Imprimis Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the “Company” or “Imprimis”) is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states. The Company’s unique business model increases patient access and affordability to many critical medicines. Headquartered in San Diego, California, Imprimis owns and operates production and dispensing facilities located in California and New Jersey.

Basis of Presentation

Imprimis has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for audited financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or for any other period. For further information, refer to the Company’s audited consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following represents an update for the three and six months ended June 30, 2017 to the significant accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

Liquidity

The Company has incurred significant operating losses and negative cash flows from operations since its inception. The Company incurred net losses of $3,522 and $9,135 for the six months ended June 30, 2017 and 2016, respectively, and had an accumulated deficit of $80,373 and $76,851 as of June 30, 2017 and December 31, 2016, respectively. In addition, the Company used cash in operating activities of $6,285 and $5,068 for the six months ended June 30, 2017 and 2016, respectively.

While there is no assurance, the Company believes its existing cash resources and restricted cash of approximately $4,365 at June 30, 2017, along with proceeds from the SWK Loan (see Notes 10 and 15), will be sufficient to sustain the Company’s planned level of operations for at least the next twelve months. However, estimates of operating expenses and working capital requirements could be incorrect, and the Company could use its cash resources faster than anticipated. Further, some or all of the ongoing or planned activities may not be successful and could result in further losses.

The Company may seek to increase liquidity and capital resources by one or more measures, to the extent necessary. These measures may include, but are not limited to, the following: the sale of assets and/or businesses, obtaining financing through the issuance of equity, debt, or convertible securities; and working to increase revenue growth through pharmacy sales. There is no guarantee that the Company will be able to obtain capital when needed on terms it deems as acceptable, or at all.

Revenue Recognition and Deferred Revenue

The Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The Company’s revenues consist of sales of certain of the Company’s proprietary compounded drug formulations and non-proprietary formulations and products.

Product Revenues

Determination of criteria (3) and (4) is based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related sales are recorded. The Company will defer any revenues received for a product that has not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.

License Revenues

License arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.

Non-refundable fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the part of the Company are recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company’s performance under the other elements of the arrangement. In addition, if the Company’s continued involvement is required, through research and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.

Investment in Eton Pharmaceuticals, Inc.

In April 2017, the Company formed Eton Pharmaceuticals, Inc. (“Eton”) as a wholly owned subsidiary. In June 2017, Eton entered into and closed on definitive stock purchase agreements with accredited investors for the purchase of Eton’s Series A Preferred Stock that resulted in net proceeds to Eton, after deducting placement agent fees and other expenses, of approximately $18,000. At the time of closing, the Company lost voting and ownership control of Eton and it ceased consolidating Eton’s financial statements. At the time of deconsolidation, the Company recorded a gain of $5,725 and adjusted the carrying value in Eton to reflect the increased valuation of Eton and the Company’s new ownership percent in accordance with Accounting Standard Codification (“ASC”) 810-10-40-4(c), Consolidation.

The Company owns 3,500,000 common shares (approximately 27% equity interest as of June 30, 2017) of Eton and, uses the equity method of accounting for this investment, as management has determined that the Company has the ability to exercise significant influence over the operating and financial decisions of Eton. Under this method, the Company recognizes earnings and losses of Eton in its financial statements and adjusts the carrying amount of its investment in Eton accordingly. The Company’s share of earnings and losses are based on the shares of common stock and in-substance common stock of Eton held by the Company. Any intra-entity profits and losses are eliminated. During the three and six months ended June 30, 2017, the Company recorded equity in net loss of Eton of $216. As of June 30, 2017, the carrying value of the Company’s investment in Eton was $5,509.

Basic and Diluted Net Income (Loss) per Common Share

Basic net income (loss) per common share is computed by dividing income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during the period.

Basic and diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock or “if converted” method) from deferred acquisition obligations, convertible note payable, stock options, unvested restricted stock units (“RSUs”) and warrants were 9,404,755 and 4,341,044 at June 30, 2017 and 2016, respectively, and, except for the three months ended June 30, 2017, are excluded from the calculation of diluted net (loss) per share for the periods presented, because the effect is anti-dilutive. Included in the basic and diluted net income (loss) per share calculation were RSUs awarded to directors that had vested, but the issuance and delivery of the shares are deferred until the director resigns. The number of shares underlying vested RSUs at June 30, 2017 and 2016 was 105,621 and 266,621, respectively.

The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016
Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		20,209,821		13,332,645			19,572,051			11,870,037
Net income (loss) per share, basic	$	0.07	$	(0.35	)	$	(0.18	)	$	(0.77	)

For the three months ended June 30, 2017, the Company had net income. As a result, the Company computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods. Diluted common equivalent shares for the three months ended June 30, 2017, consisted of the following:

	Shares
Diluted shares related to:
Warrants		2,912,374
Stock options		55,686
Dilutive common equivalent shares		2,968,060

The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016

Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		23,177,881		13,332,645			19,572,051			11,870,037
Dilutive common equivalents		2,968,860		-			-			-
Number of shares used for diluted earnings per share computation		23,177,881		13,332,645			19,572,051			11,870,037
Net income (loss) per share, diluted	$	0.06	$	(0.35	)	$	(0.18	)	$	(0.77	)

Recently Adopted Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which addresses certain aspects of accounting for share-based payment award transactions. The Company adopted this standard on January 1, 2017. The adoption did not have a material impact on the Company’s financial position, results of operations and cash flows. Prior periods were not recast.

In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory, which requires entities to measure most inventory “at the lower of cost and net realizable value (“NRV”),” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market. Under the new guidance, inventory is “measured at the lower of cost and net realizable value,” which eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.” The Company adopted this standard on January 1, 2017. The adoption did not have a material impact on the Company’s financial position, results of operations and cash flows. Prior periods were not recast.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. This updated guidance supersedes the current revenue recognition guidance, including industry-specific guidance. The updated guidance introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The updated guidance is effective for interim and annual periods beginning after December 15, 2016, and early adoption is not permitted. In July 2015, the FASB decided to delay the effective date of ASU 2014-09 until December 15, 2017. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. The Company is currently evaluating which transition method it will adopt and the expected impact of the updated guidance, but does not believe the adoption of the updated guidance will have a significant impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires the lease rights and obligations arising from lease contracts, including existing and new arrangements, with terms more than 12 months to be recognized as assets and liabilities on the balance sheet. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. The amendments also require certain quantitative and qualitative disclosures about leasing arrangements. ASU 2016-02 is effective for reporting periods beginning after December 15, 2018 with early adoption permitted. While the Company is still evaluating ASU 2016-02, the Company expects the adoption of ASU 2016-02 to have a material effect on the Company’s consolidated financial condition due to the recognition of the lease rights and obligations as assets and liabilities. The Company does not expect ASU 2016-02 to have a material effect on the Company’s results of operations and cash flows.

In January 2017, the FASB issued ASU 2017-01, Business Combinations, Clarifying the Definition of a Business, which revises the definition of a business and provides new guidance in evaluating when a set of transferred assets and activities is a business. ASU 2017-01 is effective for reporting periods beginning after December 15, 2017 with early adoption permitted. The Company does not expect the ASU 2017-01 to have a material impact on the Company’s financial position, results of operations and cash flows.

In January 2017, the FASB issued ASU 2017-04, Intangibles-Goodwill and Other. This guidance simplifies the accounting for goodwill impairment for all entities by requiring impairment charges to be based on the first step in the current two-step impairment test under ASC 350. The updated standard eliminates the requirement to calculate a goodwill impairment charge using Step 2. If a reporting unit’s carrying amount exceeds its fair value, an entity will record an impairment charge based on that difference. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. ASU 2017-04 is effective for reporting periods beginning after December 31, 2019 on a prospective basis, and early adoption is permitted. The Company does not expect ASU 2017-04 to have a material effect on the Company’s financial position, results of operations and cash flows.

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions

6 Months Ended

Jun. 30, 2017

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions

NOTE 3. INVESTMENT IN ETON PHARMACEUTICALS, INC. AND AGREEMENTS - RELATED PARTY TRANSACTIONS

In May 2017, the Company entered into two asset purchase and license agreements (the “Eton License Agreements”) with its previously wholly owned subsidiary, Eton. Pursuant to the terms of the Eton License Agreements, the Company assigned and licensed to Eton certain intellectual property and related rights to develop, formulate, make, sell, and sub-license formulations of synthetic corticotropin and injectable pentoxifylline (collectively, the “Eton Products”). Eton is required to make royalty payments to the Company of six percent (6%) of net sales of the Eton Products while any patent rights remain outstanding and then three percent (3%) of net sales thereafter. In addition, Eton is required to make certain milestone payments to the Company including payments of $50,000 upon initial patent issuances for each Eton Product. The Eton License Agreements were conditioned upon Eton receiving net proceeds of the sale of its equity securities of not less than $10,000, which occurred in June 2017. See also Note 2, under the subheading Investment in Eton Pharmaceuticals, Inc.

On May 1, 2017, the Company and Eton entered into a Management Services Agreement (the “MSA”), whereby the Company will provide to Eton certain administrative services and support, including bookkeeping, web services and human resources related activities, and Eton will pay the Company a monthly amount of $10. The MSA is terminable by either party upon written notice.

During the three and six months ended June 30, 2017, the Company incurred expenses that are reimbursable by Eton totaling $47, and no payments were made by Eton to the Company. As of June 30, 2017, the Company was due $67 from Eton for reimbursable expenses and amounts due under the MSA and included in prepaid expenses and other current assets on the accompanying condensed consolidated balance sheets.

The Company owns approximately 27% of Eton. The Company’s Chief Executive Officer, Mark L. Baum, is a director of Eton, and several employees of the Company (including Mr. Baum and the Company’s Chief Financial Officer, Andrew R. Boll) have entered into consulting agreements with Eton.

The unaudited condensed results of operations information of Eton is summarized below (in thousands):

	From the period beginning
	April 27, 2017 (inception)
	to June 30, 2017
Revenues, net	$	-
Loss from operations		477
Net loss	$	(477	)

The unaudited condensed balance sheet information of Eton is summarized below (in thousands):

	At June 30,
	2017
Current assets	$	18,134
Total assets		18,134

Current liabilities		147
Stockholders’ equity		17,987
Total liabilities and stockholders’ equity	$	18,134

Restricted Cash

6 Months Ended

Jun. 30, 2017

Cash and Cash Equivalents [Abstract]

Restricted Cash

NOTE 4. RESTRICTED CASH

The restricted cash at June 30, 2017 and December 31, 2016 consisted of funds held in a money market account. At June 30, 2017 and December 31, 2016, the restricted cash was recorded at amortized cost, which approximates fair value.

At June 30, 2017 and December 31, 2016, the funds held in a money market account of $200 were classified as a current asset. The money market account funds are required as collateral as additional security for the Company’s New Jersey facility lease.

Inventories

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventories

NOTE 5. INVENTORIES

Inventories are comprised of finished compounded formulations, over-the-counter and prescription retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients. The composition of inventories as of June 30, 2017 and December 31, 2016 was as follows:

	June 30,		December 31,
	2017		2016
Raw materials	$	494	$	669
Finished goods		1,338		1,172
Total inventories	$	1,832	$	1,841

Prepaid Expenses and Other Current Assets

6 Months Ended

Jun. 30, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

	June 30,		December 31,
	2017		2016
Prepaid insurance	$	535	$	315
Other prepaid expenses		49		517
Deposits and other current assets		202		106
Total prepaid expenses and other current assets	$	786	$	938

Asset Sales and Held For Sale

6 Months Ended

Jun. 30, 2017

Asset Sales And Held For Sale

Asset Sales and Held For Sale

NOTE 7. ASSET SALES AND HELD FOR SALE

On June 27, 2017, the Company entered into an Asset Purchase Agreement (the “PA Agreement”) with Creative Pharmacy Solutions Central, LLC (the “Buyers”). Under the terms of the PA Agreement, the Company sold substantially all its assets associated with its sinus related business, including but not limited to, certain intellectual property rights, trademarks, copyrights, inventories, equipment, customer lists, databases, permits, licenses, and assignment of the Company’s lease obligation for its Pennsylvania based pharmacy (the “PA Assets”), for a total purchase price of approximately $450.

Under the terms of the PA Agreement, the Buyers, upon closing, paid to the Company an aggregate cash amount of $40. In addition, the Buyers are obligated to pay the remaining $410 in the form of a note that will bear interest at 6% per annum (the “Sellers Note”). The Buyers will make forty-eight monthly cash payments to the Company of $10 each month over the four years following the closing, totaling $462; provided however, that the Buyer will have the option to make a one-time payment of $365 any time prior to December 31, 2017, and the Company will waive any remaining amounts due on the Sellers Note. The principal amount of the Sellers Note may also be reduced by $125, if after a period of 60 days following the closing, certain revenues associated with the PA Assets are less than 60% of the revenues associated with the PA Assets during the 60 days prior to the close of the transaction. The closing of this transaction occurred on July 14, 2017.

At June 30, 2017, the Company has listed the PA Assets on its condensed consolidated balance sheet as held for sale, and during the three and six months ended June 30, 2017, recorded a loss related to the PA Assets of $69.

In June 2017, in a separate transaction, the Company entered into an agreement to sell certain equipment to a third party for amount of $70. The Company has listed this equipment on its condensed consolidated balance sheet as held for sale, and during the three and six months ended June 30, 2017, recorded a loss related to equipment of $42.

Assets held for sale consisted of the following:

	June 30,
	2017
Inventories	$	413
Furniture and equipment		218
		631
Loss on asset sale		(111	)
Assets available for sale	$	520

In February 2017, the Company entered into a stock purchase agreement (the “SPA”) with Livernois & London, LLC (“Livernois”). Pursuant to the terms of the SPA, the Company sold to Livernois 100% of the issued and outstanding shares of common stock of its Texas based subsidiary, ImprimisRx TX, Inc. dba ImprimisRx (“Imprimis TX”). The SPA did not transfer to Livernois any of the Company’s rights to intellectual property, products, clients, nor any of its existing business operations. As consideration for the purchase of Imprimis TX, Livernois paid the Company $10 and the Company assigned, and Livernois assumed, the remaining lease obligation totaling $113 for the Texas based facility. The Company recorded a loss of $158 and $173 from the sale of Imprimis TX for the three and six months ended June 30, 2017, respectively, which is included in the accompanying condensed consolidated statements of operations.

Intangible Assets and Goodwill

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

NOTE 8. INTANGIBLE ASSETS AND GOODWILL

The Company’s intangible assets at June 30, 2017 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	287	$	(14	)	$	-		$	273
Licenses	20 years		50		-			-			50
Trademarks	Indefinite		244		-			-			244
Customer relationships	3-15 years		2,998		(683	)		(15	)		2,299
Trade name	5 years		16		(8	)		(1	)		7
Non-competition clause	3-4 years		294		(228	)		(20	)		45
State pharmacy licenses	25 years		45		(3	)		(28	)		14
		$	3,934	$	(936	)	$	(64	)	$	2,934

Amortization expense for intangible assets for the three and six months ended June 30 was as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30,		June 30,		June 30,		June 30,
	2017		2016		2017		2016
Patents	$	6			$	7	$	1
Licenses		-		-		-		-
Customer relationships		63	$	66		127		260
Trade name		1		1		2		3
Non-competition clause		22		23		44		90
State pharmacy licenses		-		1		1		1
	$	92	$	91	$	181	$	355

Estimated future amortization expense for the Company’s intangible assets at June 30, 2017 is as follows:

Remainder of 2017	$	182
2018		222
2019		218
2020		216
2021		216
Thereafter		1,880
	$	2,934

There have been no changes in the carrying value of the Company’s goodwill during the six months ended June 30, 2017.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accounts Payable and Accrued Expenses

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

NOTE 9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consisted of the following:

	June 30,			December 31,
	2017			2016
Accounts payable	$	2,833		$	2,999
Deferred rent		380			412
Accrued interest		131			116
Accrued exit fee for note payable		667			667
Building lease liability		-			11
Total accounts payable and accrued expenses		4,011			4,205
Less: current portion		(3,344	)		(3,538	)
Non-current total accrued expenses	$	667		$	667

Debt

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Debt

NOTE 10. DEBT

The Company and Life Sciences Alternative Funding, LLC (“LSAF”) originally entered into a loan and security agreement (the “LSAF Loan”) on May, 11, 2015, which was most recently amended on December 27, 2016. At June 30, 2017, the outstanding principal balance was $12,732 and the related unamortized discount was $884. The discount is being amortized to interest expense over the term of the note using the effective interest method. During the three and six months ended June 30, 2017, debt discount amortization related to notes payable were $251 and $539, respectively, and $264 and $526 during the three and six months ended June 30, 2016, respectively.

In July 2017, the Company entered into a term loan and security agreement in the principal amount of $16,000 (the “SWK Loan Agreement” or “SWK Loan”) with SWK Funding LLC and its partners (the “SWK”), as lender and collateral agent. The SWK Loan Agreement was fully funded at closing with a five year term, however, such term may be reduced to four years if certain revenue requirements are not achieved. Concurrently with the funding, the Company utilized a portion of the SWK Loan funds as full payment to an affiliate of LSAF to terminate all amounts due to LSAF in connection with the LSAF Loan, which loan had a principal balance of $12,120 at the time of final payment. As a result of entering into the SWK Loan Agreement and concurrent retirement of the LSAF Loan, at June 30, 2017, the Company has classified the amounts due as long term on its condensed consolidated balance sheet as of June 30, 2017.

The SWK Loan bears interest at a variable rate equal to the three-month London Inter-Bank Offered Rate (subject to a minimum of 1.50% and maximum of 3.00%), plus an applicable margin of 10.50%. The SWK Loan Agreement permits the Company to pay interest only on the principal amount loaned thereunder for the first six payments (payments are due on a quarterly basis), which interest-only period may be reduced to four payments if the Company does not meet certain minimum revenue requirements. Following the interest-only period, the Company will be required to pay interest, plus repayments of the principal amount loaned under the SWK Loan Agreement, in quarterly payments, which shall not exceed $750 per quarter. All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, will be due and payable on July 19, 2022, or if certain revenue requirements are not met, July 19, 2021. The Company may elect to prepay all, but not less than all, of the amounts owed under the SWK Loan Agreement prior to the maturity date at any time after July 19, 2019. If certain revenue requirements are not met, the Company may be allowed to prepay the loan from July 19, 2018 to July 19, 2019, provided that a prepayment fee equal to 6% of the principal amount of the loan will also be due. The Company is also obligated under the SWK Loan Agreement to pay for certain expenses incurred by the SWK Lender through and after the date of the SWK Loan Agreement, including certain fees and expenses relating to the preparation and administration of the SWK Loan Agreement.

In connection with the SWK Loan Agreement, the Company issued to the SWK Lender warrants to purchase up to 415,586 shares of the Company’s common stock (the “Lender Warrants”). The Lender Warrants are exercisable immediately, have an exercise price of $3.08 per share and a term of 7 years. The SWK Lender Warrants are subject to a cashless exercise feature, with the exercise price and number of shares issuable upon exercise subject to change in connection with stock splits, dividends, reclassifications and other conditions.

Capital Lease Obligation

6 Months Ended

Jun. 30, 2017

Leases [Abstract]

Capital Lease Obligation

NOTE 11. CAPITAL LEASE OBLIGATION

At June 30, 2017, future payments under the Company’s capital leases were as follows:

	Amount
Remainder of 2017	$	387
2018		773
2019		751
Total minimum lease payments		1,911
Less: amount representing interest payments		(163	)
Present value of future minimum lease payment		1,748
Less: unamortized discount		(184	)
		1,564
Less: current portion, net of unamortized discount		(526	)
Capital lease obligation net of current portion and unamortized discount	$	1,038

For the three and six months ended June 30, 2017, debt discount amortization related to the capital lease obligation was $44 and $93, respectively.

Stockholders' Equity and Stock-based Compensation

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' Equity and Stock-based Compensation

NOTE 12. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION

Common Stock

In March 2017, we entered into securities purchase agreements with two accredited investors, which provided for the sale by the Company of 1,312,500 shares of its common stock, at a price of $2.40 per share (the “Registered Offering”). We received net proceeds of $2,940 after deducting the underwriter discount of 6% of the gross proceeds from the Registered Offering and other related expenses.

In March 2017, the Company issued 25,000 shares of its restricted common stock, with a fair value of $60, as payment for investor relations related services.

In April 2017, the Company issued 100,000 shares of common stock as a result of warrant exercises. The Company received cash proceeds of $179 upon the exercise of the warrants with an exercise price of $1.79.

In November 2015, the Company entered into a Controlled Equity Offering^SM sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time through Cantor Fitzgerald, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the Securities and Exchange Commission. The Company agreed to pay Cantor Fitzgerald a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. The Company did not sell any shares of common stock under the Sales Agreement during the six months ended June 30, 2017.

During the six months ended June 30, 2017, 25,376 shares of the Company’s common stock underlying RSUs issued to directors vested, but the issuance and delivery of these shares are deferred until the director resigns.

Stock Option Plan

On September 17, 2007, the Company’s Board of Directors and stockholders adopted the Company’s 2007 Incentive Stock and Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the “2007 Plan”). On June 13, 2017, the Company’s Board of Directors and stockholders adopted the Company’s 2017 Incentive Stock and Awards Plan (the “2017 Plan” together with the 2007 Plan, the “Plans”)). As of June 30, 2017, the 2007 Plan and 2017 Plan provide for the issuance of a maximum of 5,000,000 and 2,000,000 shares of the Company’s common stock, respectively. The purpose of the Plans is to attract and retain directors, officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons in the Company’s development and financial success. Under the Plans, the Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, restricted stock units and restricted stock. The Plans are administered by the Compensation Committee of the Company’s Board of Directors.

Stock Options

A summary of stock option activity under the Plans for the six months ended June 30, 2017 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2017		2,013,313		$	6.20
Options granted		397,500		$	2.58
Options exercised		-		$	-
Options cancelled/forfeit		(111,147	)	$	4.98
Options outstanding - June 30, 2017		2,299,666		$	5.63		6.68	$	412,810
Options exercisable		854,582		$	6.06		6.40	$	129,100
Options vested and expected to vest		2,155,157		$	5.65		6.52	$	384,439

The aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price on June 30, 2017, based on the closing price of the Company’s common stock of $3.20 on that date.

During the six months ended June 30, 2017, the Company granted stock options to certain employees. The stock options were granted with an exercise price equal to the current market price of the Company’s common stock, as reported by the securities exchange on which the common stock was then listed, at the grant date and have contractual terms of 10 years. Vesting terms for options granted to employees and consultants during the six months ended June 30, 2017 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.

The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The expected volatility is based on the historical volatilities of the common stock of the Company and comparable publicly traded companies based on the Company’s belief that it currently has limited relevant historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The expected term of options granted to employees and directors was determined in accordance with the “simplified approach,” as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2017
Weighted-average fair value of options granted	$	2.21
Expected terms (in years)		5.81 - 6.11
Expected volatility		117 - 112	%
Risk-free interest rate		1.82 – 2.01	%
Dividend yield		-

The following table summarizes information about stock options outstanding and exercisable at June 30, 2017:

		Options Outstanding						Options Exercisable
				Weighted
				Average		Weighted				Weighted
				Remaining		Average				Average
		Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices		Outstanding		Life in Years		Price		Exercisable		Price
$	2.23 - $2.60		462,000		8.23	$	2.31		147,499	$	2.37
$	3.53 - $4.50		683,623		8.40	$	3.98		222,164	$	4.05
$	5.49 - $6.36		110,100		6.18	$	5.97		102,282	$	5.97
$	6.64 - $8.99		1,038,913		4.60	$	7.98		377,607	$	8.21
$	42.80		5,030		3.12	$	42.80		5,030	$	42.80
$	2.23 - $42.80		2,299,666		6.68	$	5.63		854,582	$	6.06

As of June 30, 2017, there was approximately $3,132 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of 2.8 years. The stock-based compensation expense for all stock options was $500 and $950 during the three and six months ended June 30, 2017, respectively.

Restricted Stock Units

RSU awards are granted subject to certain vesting requirements and other restrictions, including performance and market-based vesting criteria. The grant date fair value of the RSUs, which has been determined based upon the market value of the Company’s common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting criteria is met.

A summary of the Company’s RSU activity and related information for the six months ended June 30, 2017 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2017		1,292,876		$	2.43
RSUs granted		62,892		$	3.18
RSUs vested		(25,376	)	$	3.94
RSUs cancelled/forfeit		-		$
RSUs unvested at June 30, 2017		1,330,392		$	2.44

As of June 30, 2017, the total unrecognized compensation expense related to unvested RSUs was approximately $1,932, which is expected to be recognized over a weighted-average period of 1.3 years, based on estimated and actual vesting schedules of the applicable RSUs. The stock-based compensation for RSUs during the three and six months ended June 30, 2017 was $169 and $607.

Warrants

From time to time, the Company issues warrants to purchase shares of the Company’s common stock to investors, lenders, underwriters, settlement agreements and other non-employees for services rendered or to be rendered in the future.

A summary of warrant activity for the six months ended June 30, 2017 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2017		5,748,829		$	1.91
Granted		-
Exercised		(100,000	)		1.79
Expired		-
Warrants outstanding and exercisable - June 30, 2017		5,648,829		$	1.91
Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2017		2.59

A list of the warrants outstanding as of June 30, 2017 is included in the following table:

	Warrants Outstanding						Warrants Exercisable
			Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date		Outstanding		Price		Exercisable		Date
Lender warrants		5/11/2015		125,000	$	1.79		125,000		5/11/2025
Underwriter warrants		2/7/2013		55,688	$	5.25		55,688		2/7/2018
Settlement warrants		8/16/2016		40,000	$	3.75		40,000		8/16/2021
Warrants issued to investor relations consultant		7/19/2013		60,000	$	8.50		60,000		7/19/2018
Placement Agent Warrants		12/27/2016		210,313	$	1.79		210,313		12/27/2019
PIPE Investor Warrants		12/27/2016		5,157,828	$	1.79		5,157,828		12/27/2019
				5,648,829	$	1.91		5,648,829

The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:

	For the Three Months Ended		For the Three Months Ended		For the Six Months Ended		For the Six Months Ended
	June 30, 2017		June 30, 2016		June 30, 2017		June 30, 2016
Employees - selling and marketing	$	107	$	126	$	242	$	246
Employees - general and administrative		510		980		1,210		1,865
Directors - general and administrative		50		55		105		114
Consultants - selling and marketing		-		-		60		-
Total	$	667	$	1,161	$	1,617	$	2,225

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

NOTE 13. COMMITMENTS AND CONTINGENCIES

Legal

General and Other

In the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal actions to assert the Company’s rights, including intellectual property disputes, contractual disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims are not likely to have a material effect on the Company’s consolidated financial position and results of operations.

Indemnities

In addition to the indemnification provisions contained in the Company’s charter documents, the Company generally enters into separate indemnification agreements with each of the Company’s directors and officers. These agreements require the Company, among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys’ fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of the individual’s status or service as the Company’s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities in the accompanying condensed consolidated balance sheets.

Asset Purchase, License and Commission Agreements

The Company has acquired intellectual property rights related to certain proprietary innovations from certain inventors (the “Inventors”) through multiple asset purchase, license and commission agreements. In consideration for the acquisition of the intellectual property rights, the Company is obligated to make certain milestone payments related to patent and regulatory filings to the Inventors and also make payments, in one instance a minimum annual amount, based on certain percentages of revenues and net sales amounts, as defined within the respective agreements. During the six months ended June 30, 2017 and 2016, the Company recognized $21 and $361, respectively, in expense amounts related to these agreements. Such amounts are included in cost of sales and sales and marketing expenses in the accompanying condensed consolidated statements of operations.

Klarity License Agreement – Related Party

In April 2017, the Company entered into a license agreement (the “Klarity License Agreement”) with Richard L. Lindstrom, M.D., a member of its Board of Directors. Pursuant to the terms of the Klarity License Agreement, the Company licensed certain intellectual property and related rights from Dr. Lindstrom to develop, formulate, make, sell, and sub-license the topical ophthalmic solution Klarity used to protect and rehabilitate the ocular surface (the “Klarity Product”).

Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold. In addition, the Company is required to make certain milestone payments to Dr. Lindstrom including: (i) an initial payment of $50 upon execution of the Klarity License Agreement, (ii) a second payment of $50 following the first $50 in net sales of the Klarity Product; and (iii) a final payment of $50 following the first $100 in net sales of the Klarity Product. All of the above referenced milestone payments are payable at the Company’s election in cash or shares of the Company’s restricted common stock. Dr. Lindstrom was paid $50 during the three and six months ended June 30, 2017. Dr. Lindstrom is a member of the Company’s Board of Directors, chairman of its Compensation Committee and a member of its Nomination and Corporate Governance Committee.

Sales and Marketing Agreement – Precision Lens

In April 2017, the Company entered into a Strategic Sales & Marketing Agreement (the “Plens Agreement”) with Cameron Ehlen Group, Inc. dba Precision Lens (“Precision Lens”). Pursuant to the terms of the Plens Agreement, Precision Lens will provide exclusive sales and marketing representation services to Imprimis in select geographies in the U.S. Midwest, in connection with the our ophthalmic compounded formulation portfolio including our Dropless Therapy®, LessDrops® combination eye drops, Simple Drops™ preservative-free glaucoma drops, MKO Melt™ conscious sedation and other ocular-related formulations typically used for dilation, general inflammation and infection (the “Products”).

Under the terms of the Plens Agreement, the Company is required to make commission payments to Precision Lens equal to 10% of each calendar year’s annual net sales for Products above and beyond the Company’s initial $1,500 in annual net sales for Products for each calendar year. In addition, the Company is required to make periodic milestone payments to Precision Lens in shares of the Company’s restricted common stock including: (i) 10,000 shares if net sales for Products reach $5,000 prior to December 31, 2017; (ii) 15,000 shares if net sales for Products reach $5,000; (iii) 15,000 shares if net sales for Products reach $10,000; (iv) 15,000 shares if net sales for Products reach $15,000; and (v) 15,000 shares if net sales for Products reach $20,000. No payments have been made in relation to this agreement as of June 30, 2017.

Sales and Marketing Agreement – SightLife

In April 2017, the Company entered into a Strategic Sales & Marketing Agreement (the “SightLife Agreement”) with SightLife Surgical, Inc. (“SightLife”). Pursuant to the terms of the SightLife Agreement, SightLife will provide exclusive United States sales and marketing representation services to the Company in connection with the Company’s Serum Tears™ autologous serum tears formulation (the “ASED Products”) for dry eye disease.

Under the terms of the SightLife Agreement, the Company is required to make commission payments to SightLife equal to 10% of each calendar year’s annual net sales for ASED Products. In addition, the Company is required to make periodic milestone payments to SightLife in shares of the Company’s restricted common stock including: (i) 5,000 shares if net sales for ASED Products reach $2,000 prior to December 31, 2017; (ii) 7,500 shares if net sales for ASED Products reach $2,500; (iii) 7,500 shares if net sales for ASED Products reach $5,000; (iv) 7,500 shares if net sales for ASED Products reach $7,500; and (v) 7,500 shares if net sales for ASED Products reach $10,000. No payments have been made in relation to this agreement as of June 30, 2017.

Segment Information and Concentrations

6 Months Ended

Jun. 30, 2017

Segment Reporting [Abstract]

Segment Information and Concentrations

NOTE 14. SEGMENT INFORMATION AND CONCENTRATIONS

The Company operates its business on the basis of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Company’s chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.

The Company categorizes revenues by geographic area based on selling location. All operations are currently located in the U.S.; therefore, total revenues for 2017 and 2016 are attributed to the U.S. All long-lived assets at June 30, 2017 and December 31, 2016 are located in the U.S.

The Company sells its compounded formulations to a large number of customers. Less than 10% of the Company’s total pharmacy sales were derived from a single customer for the three and six months ended June 30, 2017 and 2016.

The Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 72% and 77% during the three and six months ended June 30, 2017, respectively, and 86% and 71% during the three and six months ended June 30, 2016, respectively, of active pharmaceutical ingredient purchases.

Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events

NOTE 15. SUBSEQUENT EVENTS

The Company has performed an evaluation of events occurring subsequent to June 30, 2017 through the filing date of this Quarterly Report. Based on its evaluation, nothing other than the events described below needs to be disclosed.

Loan Agreement

In July 2017, the Company entered into a term loan and security agreement with SWK Funding LLC and its partners, and terminated all amounts due to LSAF in connection with the exiting term loan and security agreements as described in Note 10.

Sale of PA and Sinus Assets

In July 2017, the Company completed the disposition of substantially all its assets associated with its sinus related business as described in Note 7.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Liquidity

Liquidity

Revenue Recognition and Deferred Revenue

Revenue Recognition and Deferred Revenue

Product Revenues

License Revenues

Investment in Eton Pharmaceuticals, Inc.

Investment in Eton Pharmaceuticals, Inc.

Basic and Diluted Net Income (Loss) per Common Share

Basic and Diluted Net Income (Loss) per Common Share

The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016
Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		20,209,821		13,332,645			19,572,051			11,870,037
Net income (loss) per share, basic	$	0.07	$	(0.35	)	$	(0.18	)	$	(0.77	)

	Shares
Diluted shares related to:
Warrants		2,912,374
Stock options		55,686
Dilutive common equivalent shares		2,968,060

The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016

Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		23,177,881		13,332,645			19,572,051			11,870,037
Dilutive common equivalents		2,968,860		-			-			-
Number of shares used for diluted earnings per share computation		23,177,881		13,332,645			19,572,051			11,870,037
Net income (loss) per share, diluted	$	0.06	$	(0.35	)	$	(0.18	)	$	(0.77	)

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Schedule of Basic Earnings Per Common Share

The following table shows the computation of basic net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016
Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		20,209,821		13,332,645			19,572,051			11,870,037
Net income (loss) per share, basic	$	0.07	$	(0.35	)	$	(0.18	)	$	(0.77	)

Schedule of Diluted Common Equivalent Shares

Diluted common equivalent shares for the three months ended June 30, 2017, consisted of the following:

	Shares
Diluted shares related to:
Warrants		2,912,374
Stock options		55,686
Dilutive common equivalent shares		2,968,060

Schedule of Diluted Earnings Per Common Share

The following table shows the computation of diluted net income (loss) per share of common stock for the three and six months ended June 30, 2017 and 2016:

	For the Three Months Ended		For the Three Months Ended			For the Six Months Ended			For the Six Months Ended
	June 30, 2017		June 30, 2016			June 30, 2017			June 30, 2016

Numerator – net income (loss)	$	1,484	$	(4,639	)	$	(3,522	)	$	(9,135	)
Denominator – weighted average number of shares outstanding, basic		23,177,881		13,332,645			19,572,051			11,870,037
Dilutive common equivalents		2,968,860		-			-			-
Number of shares used for diluted earnings per share computation		23,177,881		13,332,645			19,572,051			11,870,037
Net income (loss) per share, diluted	$	0.06	$	(0.35	)	$	(0.18	)	$	(0.77	)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2017

Schedule of Condensed Income Statement

The unaudited condensed results of operations information of Eton is summarized below (in thousands):

	From the period beginning
	April 27, 2017 (inception)
	to June 30, 2017
Revenues, net	$	-
Loss from operations		477
Net loss	$	(477	)

Schedule of Condensed Balance Sheet

The unaudited condensed balance sheet information of Eton is summarized below (in thousands):

	At June 30,
	2017
Current assets	$	18,134
Total assets		18,134

Current liabilities		147
Stockholders’ equity		17,987
Total liabilities and stockholders’ equity	$	18,134

Inventories (Tables)

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

The composition of inventories as of June 30, 2017 and December 31, 2016 was as follows:

	June 30,		December 31,
	2017		2016
Raw materials	$	494	$	669
Finished goods		1,338		1,172
Total inventories	$	1,832	$	1,841

Prepaid Expenses and Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2017

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

	June 30,		December 31,
	2017		2016
Prepaid insurance	$	535	$	315
Other prepaid expenses		49		517
Deposits and other current assets		202		106
Total prepaid expenses and other current assets	$	786	$	938

Asset Sales and Held for Sale (Tables)

6 Months Ended

Jun. 30, 2017

Notes to Financial Statements

Schedule of Assets Held for Sale

Assets held for sale consisted of the following:

	June 30,
	2017
Inventories	$	413
Furniture and equipment		218
		631
Loss on asset sale		(111	)
Assets available for sale	$	520

Intangible Assets and Goodwill (Tables)

6 Months Ended

Jun. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The Company’s intangible assets at June 30, 2017 consisted of the following:

	Amortization
	periods			Accumulated						Net
	(in years)	Cost		amortization			Impairment			Carrying value
Patents	17-19 years	$	287	$	(14	)	$	-		$	273
Licenses	20 years		50		-			-			50
Trademarks	Indefinite		244		-			-			244
Customer relationships	3-15 years		2,998		(683	)		(15	)		2,299
Trade name	5 years		16		(8	)		(1	)		7
Non-competition clause	3-4 years		294		(228	)		(20	)		45
State pharmacy licenses	25 years		45		(3	)		(28	)		14
		$	3,934	$	(936	)	$	(64	)	$	2,934

Schedule of Amortization Expenses for Intangible Assets

Amortization expense for intangible assets for the three and six months ended June 30 was as follows:

	For the		For the		For the		For the
	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	June 30,		June 30,		June 30,		June 30,
	2017		2016		2017		2016
Patents	$	6			$	7	$	1
Licenses		-		-		-		-
Customer relationships		63	$	66		127		260
Trade name		1		1		2		3
Non-competition clause		22		23		44		90
State pharmacy licenses		-		1		1		1
	$	92	$	91	$	181	$	355

Schedule of Estimated Future Amortization Expense

Estimated future amortization expense for the Company’s intangible assets at June 30, 2017 is as follows:

Remainder of 2017	$	182
2018		222
2019		218
2020		216
2021		216
Thereafter		1,880
	$	2,934

Accounts Payable and Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	June 30,			December 31,
	2017			2016
Accounts payable	$	2,833		$	2,999
Deferred rent		380			412
Accrued interest		131			116
Accrued exit fee for note payable		667			667
Building lease liability		-			11
Total accounts payable and accrued expenses		4,011			4,205
Less: current portion		(3,344	)		(3,538	)
Non-current total accrued expenses	$	667		$	667

Capital Lease Obligation (Tables)

6 Months Ended

Jun. 30, 2017

Leases [Abstract]

Schedule of Future Payment Under Capital Lease

At June 30, 2017, future payments under the Company’s capital leases were as follows:

	Amount
Remainder of 2017	$	387
2018		773
2019		751
Total minimum lease payments		1,911
Less: amount representing interest payments		(163	)
Present value of future minimum lease payment		1,748
Less: unamortized discount		(184	)
		1,564
Less: current portion, net of unamortized discount		(526	)
Capital lease obligation net of current portion and unamortized discount	$	1,038

Stockholders' Equity and Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Schedule of Stock Option Plan Activity

A summary of stock option activity under the Plans for the six months ended June 30, 2017 is as follows:

	Number of shares			Weighted Avg. Exercise Price		Weighted Avg. Remaining Contractual Life		Aggregate Intrinsic Value
Options outstanding - January 1, 2017		2,013,313		$	6.20
Options granted		397,500		$	2.58
Options exercised		-		$	-
Options cancelled/forfeit		(111,147	)	$	4.98
Options outstanding - June 30, 2017		2,299,666		$	5.63		6.68	$	412,810
Options exercisable		854,582		$	6.06		6.40	$	129,100
Options vested and expected to vest		2,155,157		$	5.65		6.52	$	384,439

Schedule of Fair Value Assumption

The table below illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing options granted to employees:

	2017
Weighted-average fair value of options granted	$	2.21
Expected terms (in years)		5.81 - 6.11
Expected volatility		117 - 112	%
Risk-free interest rate		1.82 – 2.01	%
Dividend yield		-

Schedule of Shares Outstanding and Exercisable

The following table summarizes information about stock options outstanding and exercisable at June 30, 2017:

		Options Outstanding						Options Exercisable
				Weighted
				Average		Weighted				Weighted
				Remaining		Average				Average
		Number		Contractual		Exercise		Number		Exercise
Range of Exercise Prices		Outstanding		Life in Years		Price		Exercisable		Price
$	2.23 - $2.60		462,000		8.23	$	2.31		147,499	$	2.37
$	3.53 - $4.50		683,623		8.40	$	3.98		222,164	$	4.05
$	5.49 - $6.36		110,100		6.18	$	5.97		102,282	$	5.97
$	6.64 - $8.99		1,038,913		4.60	$	7.98		377,607	$	8.21
$	42.80		5,030		3.12	$	42.80		5,030	$	42.80
$	2.23 - $42.80		2,299,666		6.68	$	5.63		854,582	$	6.06

Schedule of Restricted Stock Units Activity

A summary of the Company’s RSU activity and related information for the six months ended June 30, 2017 is as follows:

	Number of RSUs			Weighted Average Grant Date Fair Value
RSUs unvested - January 1, 2017		1,292,876		$	2.43
RSUs granted		62,892		$	3.18
RSUs vested		(25,376	)	$	3.94
RSUs cancelled/forfeit		-		$
RSUs unvested at June 30, 2017		1,330,392		$	2.44

Schedule of Warrants Activity

A summary of warrant activity for the six months ended June 30, 2017 is as follows:

	Number of Shares Subject to Warrants Outstanding			Weighted Avg. Exercise Price

Warrants outstanding - January 1, 2017		5,748,829		$	1.91
Granted		-
Exercised		(100,000	)		1.79
Expired		-
Warrants outstanding and exercisable - June 30, 2017		5,648,829		$	1.91
Weighted average remaining contractual life of the outstanding warrants in years - June 30, 2017		2.59

Schedule of Warrants Outstanding and Warrants Exercisable

A list of the warrants outstanding as of June 30, 2017 is included in the following table:

	Warrants Outstanding						Warrants Exercisable
			Warrants		Exercise		Warrants		Expiration
Warrant Series	Issue Date		Outstanding		Price		Exercisable		Date
Lender warrants		5/11/2015		125,000	$	1.79		125,000		5/11/2025
Underwriter warrants		2/7/2013		55,688	$	5.25		55,688		2/7/2018
Settlement warrants		8/16/2016		40,000	$	3.75		40,000		8/16/2021
Warrants issued to investor relations consultant		7/19/2013		60,000	$	8.50		60,000		7/19/2018
Placement Agent Warrants		12/27/2016		210,313	$	1.79		210,313		12/27/2019
PIPE Investor Warrants		12/27/2016		5,157,828	$	1.79		5,157,828		12/27/2019
				5,648,829	$	1.91		5,648,829

Schedule of Stock Based Compensation Granted to Employees Directors Consultants

The Company recorded stock-based compensation related to equity instruments granted to employees, directors and consultants as follows:

	For the Three Months Ended		For the Three Months Ended		For the Six Months Ended		For the Six Months Ended
	June 30, 2017		June 30, 2016		June 30, 2017		June 30, 2016
Employees - selling and marketing	$	107	$	126	$	242	$	246
Employees - general and administrative		510		980		1,210		1,865
Directors - general and administrative		50		55		105		114
Consultants - selling and marketing		-		-		60		-
Total	$	667	$	1,161	$	1,617	$	2,225

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Net loss		$ (1,484)	$ 4,639	$ 3,522	$ 9,135
Accumulated deficit	$ 80,373	80,373		80,373		$ 76,851
Net cash used in operating activities				6,285	5,068
Cash resources and restricted investments	4,365	4,365		4,365
Gain on deconsolidation of Eton Pharmaceuticals		5,725		5,725
Investment in Eton Pharmaceuticals, Inc.	5,509	5,509		5,509
Equity in loss of Eton Pharmaceuticals		$ 216		$ 216
Antidilutive securities				2,968,060
Restricted Stock Units [Member]
Number of shares vested during the period				105,621	266,621
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Antidilutive securities				9,404,755	4,341,044
Eton Pharmaceuticals, Inc. [Member]
Net loss	$ 477
Proceeds from wholly owned subsidiary				$ 18
Number of common stock shares owned				3,500,000
Equity interest percentage	27.00%	27.00%		27.00%

Summary of Significant Accounting Policies - Schedule of Basic Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Accounting Policies [Abstract]
Numerator - net loss	$ 1,484	$ (4,639)	$ (3,522)	$ (9,135)
Denominator - weighted average number of shares outstanding, basic	20,209,821	13,332,645	19,572,051	11,870,037
Net income (loss) per share, basic	$ 0.07	$ (0.35)	$ (0.18)	$ (0.77)

Summary of Significant Accounting Policies - Schedule of Diluted Common Equivalent Shares (Details)	6 Months Ended
	Jun. 30, 2017 shares
Dilutive common equivalent shares	2,968,060
Warrants [Member]
Dilutive common equivalent shares	2,912,374
Stock Options [Member]
Dilutive common equivalent shares	55,686

Summary of Significant Accounting Policies - Schedule of Diluted Earnings Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Summary Of Significant Accounting Policies - Schedule Of Diluted Earnings Per Common Share Details
Numerator - net income (loss)	$ 1,484	$ (4,639)	$ (3,522)	$ (9,135)
Denominator - weighted average number of shares outstanding, basic	20,209,821	13,332,645	19,572,051	11,870,037
Dilutive common equivalents	2,968,860
Number of shares used for diluted earnings per share computation	23,177,881	13,332,645	19,572,051	11,870,037
Net income (loss) per share, diluted	$ 0.06	$ (0.35)	$ (0.18)	$ (0.77)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions (Details Narrative) - Eton Pharmaceuticals, Inc. [Member] - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	May 31, 2017	Jun. 30, 2017	Jun. 30, 2017
Reimbursable expenses		$ 47	$ 47
Due from related parties		$ 67	$ 67
Ownership percentage		27.00%	27.00%
Eton License Agreements [Member]
Royalty payment percentage on net sales	6.00%
Outstanding percentage of net sales	3.00%
Payment on issuances of patent	$ 50
Proceeds from sale of equity securities			$ 10
Management Services Agreement [Member]
Monthly payment	$ 10

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Income Statement (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Loss from operations		$ (3,017)	$ (4,008)	$ (7,248)	$ (7,762)
Net loss		$ 1,484	$ (4,639)	$ (3,522)	$ (9,135)
Eton Pharmaceuticals, Inc. [Member]
Revenues, net
Loss from operations	477
Net loss	$ (477)

Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions - Schedule of Condensed Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets	$ 10,359	$ 14,753
Total assets	27,596	27,247
Current liabilities	5,517	9,905
Stockholders' equity	7,646	6,432
Total liabilities and stockholders' equity	27,596	$ 27,247
Eton Pharmaceuticals, Inc. [Member]
Current assets	18,134
Total assets	18,134
Current liabilities	147
Stockholders' equity	17,987
Total liabilities and stockholders' equity	$ 18,134

Restricted Cash (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Money market account	$ 200	$ 200

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 494	$ 669
Finished goods	1,338	1,172
Total inventories	$ 1,832	$ 1,841

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid insurance	$ 535	$ 315
Other prepaid expenses	49	517
Deposits and other current assets	202	106
Total prepaid expenses and other current assets	$ 786	$ 938

Asset Sales and Held for Sale (Details Narrative) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 27, 2017	Jun. 30, 2017	Feb. 28, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Loss on sale of assets				$ 158	$ 173
Pharmacy Solutions Central, LLC [Member]
Payment to closing cash amount	$ 410
Debt interest rate	6.00%
Debt monthly payment	$ 10
Debt annual principal payment	$ 462
Payment term description	The principal amount of the Sellers Note may also be reduced by $125, if after a period of 60 days following the closing, certain revenues associated with the PA Assets are less than 60% of the revenues associated with the PA Assets during the 60 days prior to the close of the transaction. The closing of this transaction occurred on July 14, 2017.
Pharmacy Solutions Central, LLC [Member] \| December 31, 2017 [Member]
Debt monthly payment	$ 365
Asset Purchase Agreement [Member]
Loss on sale of assets				69	69
Proceeds from sale of equipment		$ 70
Loss on equipment				$ 42	$ 42
Asset Purchase Agreement [Member] \| Pharmacy Solutions Central, LLC [Member]
Total purchase price	450
Payment to closing cash amount	$ 40
Stock Purchase Agreement [Member] \| Livernois [Member]
Sale of stock percentage			100.00%
Payment of consideration amount			$ 10
Lease obligation			$ 113

Asset Sales and Held for Sale - Schedule of Assets Held for Sale (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Asset Sales And Held For Sale - Schedule Of Assets Held For Sale Details
Inventories	$ 413
Furniture and equipment	218
Asset held for sale	631
Loss on asset sale	(111)
Assets available for sale	$ 520

Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Cost	$ 3,934
Accumulated amortization	(936)
Impairment	(64)
Net Carrying value	2,934
Patents [Member]
Cost	287
Accumulated amortization	(14)
Impairment
Net Carrying value	$ 273
Patents [Member] \| Minimum [Member]
Amortization periods (in years)	17 years
Patents [Member] \| Maximum [Member]
Amortization periods (in years)	19 years
Licenses [Member]
Amortization periods (in years)	20 years
Cost	$ 50
Accumulated amortization
Impairment
Net Carrying value	$ 50
Trademarks [Member]
Amortization periods description	Indefinite
Cost	$ 244
Accumulated amortization
Impairment
Net Carrying value	244
Customer Relationships [Member]
Cost	2,998
Accumulated amortization	(683)
Impairment	(15)
Net Carrying value	$ 2,299
Customer Relationships [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Customer Relationships [Member] \| Maximum [Member]
Amortization periods (in years)	15 years
Trade Name [Member]
Amortization periods (in years)	5 years
Cost	$ 16
Accumulated amortization	(8)
Impairment	(1)
Net Carrying value	7
Non-Competition Clause [Member]
Cost	294
Accumulated amortization	(228)
Impairment	(20)
Net Carrying value	$ 45
Non-Competition Clause [Member] \| Minimum [Member]
Amortization periods (in years)	3 years
Non-Competition Clause [Member] \| Maximum [Member]
Amortization periods (in years)	4 years
State Pharmacy Licenses [Member]
Amortization periods (in years)	25 years
Cost	$ 45
Accumulated amortization	(3)
Impairment	(28)
Net Carrying value	$ 14

Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Amortization of intangible assets	$ 92	$ 91	$ 181	$ 355
Patents [Member]
Amortization of intangible assets	6		7	1
Licenses [Member]
Amortization of intangible assets
Customer Relationships [Member]
Amortization of intangible assets	63	66	127	260
Trade Name [Member]
Amortization of intangible assets	1	1	2	3
Non-Competition Clause [Member]
Amortization of intangible assets	22	23	44	90
State Pharmacy Licenses [Member]
Amortization of intangible assets		$ 1	$ 1	$ 1

Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2017	$ 182
2018	222
2019	218
2020	216
2021	216
Thereafter	1,880
Intangible assets	$ 2,934	$ 2,972

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 2,833	$ 2,999
Deferred rent	380	412
Accrued interest	131	116
Accrued exit fee for note payable	667	667
Building lease liability		11
Total accounts payable and accrued expenses	4,011	4,205
Less: current portion	(3,344)	(3,538)
Non-current total accrued expenses	$ 667	$ 667

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Amortization of debt discount			$ 632	$ 526
July 2017 [Member] \| Lender Warrants [Member]
Warrant to purchase of common stock	415,586		415,586
Warrant exercise price per share	$ 3.08		$ 3.08
Warrant term			7 years
July 2017 [Member] \| London Inter-Bank Offered Rate [Member]
Loan bear interest	10.50%		10.50%
July 2017 [Member] \| London Inter-Bank Offered Rate [Member] \| Minimum [Member]
Loan bear interest	1.50%		1.50%
July 2017 [Member] \| London Inter-Bank Offered Rate [Member] \| Maximum [Member]
Loan bear interest	3.00%		3.00%
July 2017 [Member] \| Life Sciences Alternative Funding, LLC [Member]
Debt principal amount	$ 12,120		$ 12,120
SWK Loan Agreement [Member] \| July 2017 [Member]
Debt principal amount	16		$ 16
Loan agreement term			5 years
Repayment of debt			$ 750
Debt due date description			All amounts owed under the SWK Loan Agreement, including a final fee equal to 5% of the aggregate principal amount loaned thereunder, will be due and payable on July 19, 2022, or if certain revenue requirements are not met, July 19, 2021. The Company may elect to prepay all, but not less than all, of the amounts owed under the SWK Loan Agreement prior to the maturity date at any time after July 19, 2019. If certain revenue requirements are not met, the Company may be allowed to prepay the loan from July 19, 2018 to July 19, 2019, provided that a prepayment fee equal to 6% of the principal amount of the loan will also be due.
Note Payable [Member]
Debt principal amount	12,732		$ 12,732
Unamortized discount	884		884
Amortization of debt discount	$ 251	$ 264	$ 539	$ 526

Capital Lease Obligation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Debt discount amortization		$ 632	$ 526
Capital Lease Obligations [Member]
Debt discount amortization	$ 44	$ 93

Capital Lease Obligation - Schedule of Future Payment Under Capital Lease (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Leases [Abstract]
Remainder of 2017	$ 387
2018	773
2019	751
Total minimum lease payments	1,911
Less: amount representing interest payments	(163)
Present value of future minimum lease payments	1,748
Less: unamortized discount	(184)
Present value of future net minimum lease payments	1,564
Less: current portion, net of unamortized discount	(526)	$ (458)
Capital lease obligation, net of current portion and unamortized discount	$ 1,038	$ 1,318

Stockholders' Equity and Stock-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended			3 Months Ended	6 Months Ended
	Apr. 30, 2017	Mar. 31, 2017	Nov. 30, 2015	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Stock-based compensation					$ 1,617	$ 2,225
Stock Option Plan [Member]
Closing price of common stock price per share				$ 3.20	$ 3.20
Stock options granted with exercise price contractual terms					6 years 4 months 24 days
Stock options granted vesting terms					Vesting terms for options granted to employees and consultants during the six months ended June 30, 2017 typically included one of the following vesting schedules: 25% of the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest and become exercisable quarterly in equal installments thereafter over three years; or 100% vesting associated with the provision or completion of services provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event of certain modifications to the option award agreement.
Forfeiture factor, percentage					10.00%
Unrecognized compensation expense related to unvested stock options granted under the plan				$ 3,132	$ 3,132
Expense expected to recognize over the weighted-average remaining vesting period					2 years 9 months 18 days
Stock-based compensation				500	$ 950
Unvested RSUs [Member]
Unrecognized compensation expense related to unvested stock options granted under the plan				1,932	$ 1,932
Expense expected to recognize over the weighted-average remaining vesting period					1 year 3 months 19 days
Stock-based compensation				$ 169	$ 607
2007 Incentive Stock and Awards Plan [Member]
Stock options granted with exercise price contractual terms					10 years
2007 Incentive Stock and Awards Plan [Member] \| Maximum [Member]
Stock issued during period, shares, new issues					5,000,000
2007 Incentive Stock and Awards Plan [Member] \| Minimum [Member]
Stock issued during period, shares, new issues					2,000,000
Warrants [Member]
Number of common stock issued for warrant exercises	100,000
Proceeds from issuance of warrant	$ 179
Warrant exercise price per share	$ 1.79
Directors [Member]
Issuance of restricted common stock, shares					25,376
Securities Purchase Agreements [Member] \| Two Accredited Investors [Member]
Stock issued during period, shares, new issues		1,312,500
Price per share		$ 2.40
Net proceeds of registered offering		$ 2,940
Gross proceeds, percentage		6.00%
Stock Purchase Agreement [Member] \| Livernois & London, LLC [Member]
Number of shares issued investor relations related services		25,000
Number of shares issued investor relations related services, value		$ 60
Sales Agreement [Member] \| Cantor Fitzgerald & Co [Member]
Cash commission, percentage			3.00%

Stockholders' Equity and Stock-based Compensation - Schedule of Stock Option Plan Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares
Weighted Avg. Exercise Price, Exercisable Ending Balance	$ 5.63
Stock Option Plan [Member]
Number of shares, Outstanding, Beginning balance \| shares	2,013,313
Number of shares, Options granted \| shares	397,500
Number of shares, Options exercised \| shares
Number of shares, Options cancelled/forfeit \| shares	(111,147)
Number of shares, Outstanding, Ending balance \| shares	2,299,666
Number of shares, Options exercisable \| shares	854,582
Number of shares, Options vested and expected to vest \| shares	2,155,157
Weighted Avg. Exercise Price, Outstanding, Beginning balance	$ 6.20
Weighted Avg. Exercise Price, Options granted	2.58
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit	4.98
Weighted Avg. Exercise Price, Outstanding, Ending balance	5.63
Weighted Avg. Exercise Price, Exercisable Ending Balance	6.06
Weighted Avg. Exercise Price, Vested and expected to vest	$ 5.65
Weighted Avg. Remaining Contractual Life, Options outstanding	6 years 8 months 5 days
Weighted Avg. Remaining Contractual Life, Options exercisable	6 years 4 months 24 days
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest	6 years 6 months 7 days
Aggregate Intrinsic Value, Options outstanding \| $	$ 412,810
Aggregate Intrinsic Value, Options exercisable \| $	129,100
Aggregate Intrinsic Value, Options vested and expected to vest \| $	$ 384,439

Stockholders' Equity and Stock-based Compensation - Schedule of Fair Value Assumption (Details) - Options Granted to Employees [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares
Weighted-average fair value of options granted	$ 2.21
Expected volatility, minimum	117.00%
Expected volatility, maximum	112.00%
Risk-free interest rate, minimum	1.82%
Risk-free interest rate, maximum	2.01%
Dividend yield
Minimum [Member]
Expected terms (in years)	5 years 9 months 22 days
Maximum [Member]
Expected terms (in years)	6 years 1 month 9 days

Stockholders' Equity and Stock-based Compensation - Schedule of Shares Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Range of Exercise Prices, minimum	$ 2.23
Range of Exercise Prices, maximum	$ 42.80
Number of Options Outstanding \| shares	2,299,666
Weighted Average Remaining Contractual Life in Years	6 years 8 months 5 days
Weighted Average Exercise Price	$ 5.63
Number Exercisable \| shares	854,582
Weighted Average Exercisable Exercise Price	$ 6.06
Range One [Member]
Range of Exercise Prices, minimum	2.23
Range of Exercise Prices, maximum	$ 2.60
Number of Options Outstanding \| shares	462,000
Weighted Average Remaining Contractual Life in Years	8 years 2 months 23 days
Weighted Average Exercise Price	$ 2.31
Number Exercisable \| shares	147,499
Weighted Average Exercisable Exercise Price	$ 2.37
Range Two [Member]
Range of Exercise Prices, minimum	3.53
Range of Exercise Prices, maximum	$ 4.50
Number of Options Outstanding \| shares	683,623
Weighted Average Remaining Contractual Life in Years	8 years 4 months 24 days
Weighted Average Exercise Price	$ 3.98
Number Exercisable \| shares	222,164
Weighted Average Exercisable Exercise Price	$ 4.05
Range Three [Member]
Range of Exercise Prices, minimum	5.49
Range of Exercise Prices, maximum	$ 6.36
Number of Options Outstanding \| shares	110,100
Weighted Average Remaining Contractual Life in Years	6 years 2 months 5 days
Weighted Average Exercise Price	$ 5.97
Number Exercisable \| shares	102,282
Weighted Average Exercisable Exercise Price	$ 5.97
Range Four [Member]
Range of Exercise Prices, minimum	6.64
Range of Exercise Prices, maximum	$ 8.99
Number of Options Outstanding \| shares	1,038,913
Weighted Average Remaining Contractual Life in Years	4 years 7 months 6 days
Weighted Average Exercise Price	$ 7.98
Number Exercisable \| shares	377,607
Weighted Average Exercisable Exercise Price	$ 8.21
Range Five [Member]
Range of Exercise Prices, minimum	$ 42.80
Number of Options Outstanding \| shares	5,030
Weighted Average Remaining Contractual Life in Years	3 years 1 month 13 days
Weighted Average Exercise Price	$ 42.80
Number Exercisable \| shares	5,030
Weighted Average Exercisable Exercise Price	$ 42.80

Stockholders' Equity and Stock-based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Number of RSUs unvested, Outstanding, Beginning balance \| shares	1,292,876
Number of RSUs granted \| shares	62,892
Number of RSUs vested \| shares	(25,376)
Number RSUs cancelled/forfeit \| shares
Number of RSUs unvested, Outstanding, Ending balance \| shares	1,330,392
Weighted Average Grant Date Fair Value, Beginning balance \| $ / shares	$ 2.43
Weighted Average Grant Date Fair Value, RSUs granted \| $ / shares	3.18
Weighted Average Grant Date Fair Value, RSUs vested \| $ / shares	3.94
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit \| $ / shares
Weighted Average Grant Date Fair Value, Ending balance \| $ / shares	$ 2.44

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Activity (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Number of shares, outstanding, beginning balance \| shares	5,748,829
Number of shares subject to warrants outstanding, granted \| shares
Number of shares subject to warrants outstanding, exercised \| shares	(100,000)
Number of shares subject to warrants outstanding, expired \| shares
Number of shares, outstanding and exercisable , ending balance \| shares	5,648,829
Weighted average remaining contractual life of the outstanding warrants in years	2 years 7 months 2 days
Weighted avg. Exercise price, outstanding, beginning balance \| $ / shares	$ 1.91
Weighted avg. Exercise price, granted \| $ / shares
Weighted avg. Exercise price, exercised \| $ / shares	1.79
Weighted avg. Exercise price, expired/forfeited \| $ / shares
Weighted avg. Exercise price, outstanding and exercisable, ending balance \| $ / shares	$ 1.91

Stockholders' Equity and Stock-based Compensation - Schedule of Warrants Outstanding and Warrants Exercisable (Details)	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Warrant [Member]
Warrants Outstanding	5,648,829
Exercise Price \| $ / shares	$ 1.91
Warrants Exercisable	5,648,829
Lender Warrants [Member]
Issue Date	May 11, 2015
Warrants Outstanding	125,000
Exercise Price \| $ / shares	$ 1.79
Warrants Exercisable	125,000
Expiration Date	May 11, 2025
Underwriter Warrants [Member]
Issue Date	Feb. 07, 2013
Warrants Outstanding	55,688
Exercise Price \| $ / shares	$ 5.25
Warrants Exercisable	55,688
Expiration Date	Feb. 07, 2018
Settlement Warrants [Member]
Issue Date	Aug. 16, 2016
Warrants Outstanding	40,000
Exercise Price \| $ / shares	$ 3.75
Warrants Exercisable	40,000
Expiration Date	Aug. 16, 2021
Warrants Issued to Investor Relations Consultant [Member]
Issue Date	Jul. 19, 2013
Warrants Outstanding	60,000
Exercise Price \| $ / shares	$ 8.50
Warrants Exercisable	60,000
Expiration Date	Jul. 19, 2018
Placement Agent Warrants [Member]
Issue Date	Dec. 27, 2016
Warrants Outstanding	210,313
Exercise Price \| $ / shares	$ 1.79
Warrants Exercisable	210,313
Expiration Date	Dec. 27, 2019
PIPE Investor Warrants [Member]
Issue Date	Dec. 27, 2016
Warrants Outstanding	5,157,828
Exercise Price \| $ / shares	$ 1.79
Warrants Exercisable	5,157,828
Expiration Date	Dec. 27, 2019

Stockholders' Equity and Stock-based Compensation - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Stock based compensation related to equity instruments granted to related parties	$ 667	$ 1,161	$ 1,617	$ 2,225
Employees [Member] \| Selling and Marketing [Member]
Stock based compensation related to equity instruments granted to related parties	107	126	242	246
Employees [Member] \| General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	510	980	1,210	1,865
Directors [Member] \| General and Administrative [Member]
Stock based compensation related to equity instruments granted to related parties	50	55	105	114
Consultants [Member] \| Selling and Marketing [Member]
Stock based compensation related to equity instruments granted to related parties			$ 60

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Asset purchase, license and commission expense			$ 21	$ 361
Klarity License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payment description	the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% to 6% of net sales, dependent upon the final formulation of the Klarity Product sold.
Plens Agreement [Member]
Commission payments, percentage	10.00%
SightLife Agreement [Member]
Commission payments, percentage	10.00%
Initial Payment [Member] \| License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments	$ 50
Initial Payment [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	1,500
Second Payment [Member] \| License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments	50
Net sales	50
Final Payment [Member] \| License Agreement [Member] \| Richard L. Lindstrom, M.D [Member]
Royalty payments	50
Net sales	100	$ 50	50
Periodic Milestone Payments One [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	$ 5,000
Number of shares issued during the period	10,000
Periodic Milestone Payments One [Member] \| SightLife Agreement [Member] \| ASED Products [Member]
Net sales	$ 2,000
Number of shares issued during the period	5,000
Periodic Milestone Payments Two [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	$ 5,000
Number of shares issued during the period	15,000
Periodic Milestone Payments Two [Member] \| SightLife Agreement [Member] \| ASED Products [Member]
Net sales	$ 2,500
Number of shares issued during the period	7,500
Periodic Milestone Payments Three [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	$ 10,000
Number of shares issued during the period	15,000
Periodic Milestone Payments Three [Member] \| SightLife Agreement [Member] \| ASED Products [Member]
Net sales	$ 5,000
Number of shares issued during the period	7,500
Periodic Milestone Payments Four [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	$ 15,000
Number of shares issued during the period	15,000
Periodic Milestone Payments Four [Member] \| SightLife Agreement [Member] \| ASED Products [Member]
Net sales	$ 7,500
Number of shares issued during the period	7,500
Periodic Milestone Payments Five [Member] \| Plens Agreement [Member] \| Precision Lens [Member]
Net sales	$ 20,000		0
Number of shares issued during the period	15,000
Periodic Milestone Payments Five [Member] \| SightLife Agreement [Member] \| ASED Products [Member]
Net sales	$ 10,000		$ 0
Number of shares issued during the period	7,500

Segment Information and Concentrations (Details Narrative) - Segment	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Segment Reporting [Abstract]
Number of reportable segment			1
Maximum percentage of sales derived from single customer	10.00%	10.00%	10.00%	10.00%
Percentage of drug and chemical purchases from three main suppliers	72.00%	86.00%	77.00%	71.00%